Chinese Hepatolgy ›› 2021, Vol. 26 ›› Issue (12): 1320-1323.

• Liver Cancer • Previous Articles     Next Articles

The value of serum M2BPGi combined with AFP in diagnosing hepatocellular carcinoma

HONG Yu1, LIANG Shuang2, ZHU Jin-zhou   

  1. 1. Department of Gastroenterology, the First Affiliated Hospital of Soochow University, Jiangsu 215000, China;
    2. Medical School of Nantong University, Jiangsu 226001, China
  • Received:2021-02-13 Published:2022-01-13
  • Contact: ZHU Jin-zhou, Email: jzzhu@zju.edu.cn

PDF (PC)

259

Abstract: Objective To investigate the association between serum mac-2 binding protein glycan isomer (M2BPGi) level and the risk of hepatocellular carcinoma (HCC). And to investigate the value of serum M2BPGi combined with AFP in diagnosing HCC. Methods One hundred and eleven patients with HCC, 142 patients with cirrhosis and 95 patients with chronic hepatitis B (CHB) admitted to our hospital from January 2016 to October 2020 were included. Ninety-seven healthy controls were selected from physical examination center during the same period. The phase 0 and A were defined as the early HCC according to the Barcelona Clinic Liver Cancer (BCLC) classification. Serum level of M2BPGi was detected by enzyme-linked immunosorbent assay (ELISA). Binary logistic regression analysis was used to establish new variable (predicting probability). Receiver operator characteristic (ROC) curve was used to analyze the biomarkers, the area under the curve (AUC), sensitivity and specificity were evaluated. Results Serum M2BPGi level of HCC group (3.68 [2.65-5.00] C.O.I) was significantly higher than that of healthy control group (1.63 [1.34-1.90] C.O.I), CHB group (1.77 [1.23-2.16] C.O.I) and cirrhosis group (1.93 [1.54-2.50] C.O.I) (all P<0.001). After adjusting, serum level of M2BPGi was positively correlated with the risk of HCC (odd ratio 2.331, 95% CI [1.756-3.096], P<0.001). The model of serum AFP combined with M2BPGi predicting HCC was established ([AUC] 0.929, 95% CI [0.901-0.956], sensitivity 0.901, specificity 0.823, accuracy 0.843), its diagnosing value was better than AFP or M2BPGi alone (both P<0.001). The prediction model in diagnosing early HCC (AUC 0.923 [95% CI 0.887-0.960], sensitivity 0.900, specificity 0.823, accuracy 0.837) performed better than AFP (P=0.003) or M2BPGi (P<0.001) alone. Conclusion Serum M2BPGi is an independent risk factor for HCC. M2BPGi combined with AFP can improve diagnostic sensitivity in diagnosing HCC, which offers new insights in screening and early diagnosis of HCC.

Key words: Hepatocellular carcinoma, Mac-2 binding protein glycan isomer, Alpha-fetoprotein, Tumor biomarker, Real-world data